Kuros Biosciences Valuation

Is KURN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KURN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KURN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KURN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KURN?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for KURN. This is calculated by dividing KURN's market cap by their current preferred multiple.
What is KURN's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CHF 742.39m

KURN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.9x
Enterprise Value/EBITDA	-239.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does KURN's PS Ratio compare to its peers?

The above table shows the PS ratio for KURN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
IDIA Idorsia	1.9x	33.9%	CHF 248.4m
BSLN Basilea Pharmaceutica	3.7x	9.2%	CHF 550.3m
RLF Relief Therapeutics Holding	6.3x	n/a	CHF 54.2m
SANN Santhera Pharmaceuticals Holding	1x	24.5%	CHF 110.8m
KURN Kuros Biosciences	14.1x	n/a	CHF 742.4m

Price-To-Sales vs Peers: KURN is expensive based on its Price-To-Sales Ratio (14.1x) compared to the peer average (3.2x).

Price to Earnings Ratio vs Industry

How does KURN's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	34.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	34.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: KURN is expensive based on its Price-To-Sales Ratio (14.1x) compared to the European Biotechs industry average (9.1x).

Price to Sales Ratio vs Fair Ratio

What is KURN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KURN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate KURN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.